Hims & Hers Health, Inc. (NYSE:HIMS) Shares Acquired by Barclays PLC

Barclays PLC increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 9.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 308,363 shares of the company's stock after purchasing an additional 27,231 shares during the period. Barclays PLC owned 0.14% of Hims & Hers Health worth $5,680,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Main Management ETF Advisors LLC purchased a new stake in shares of Hims & Hers Health in the third quarter worth about $672,000. Robeco Institutional Asset Management B.V. purchased a new position in shares of Hims & Hers Health during the 3rd quarter worth about $604,000. Carnegie Investment Counsel bought a new position in Hims & Hers Health during the 3rd quarter valued at about $5,531,000. Royce & Associates LP raised its position in Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company's stock worth $6,281,000 after purchasing an additional 49,500 shares during the period. Finally, Versor Investments LP bought a new stake in Hims & Hers Health in the third quarter worth about $634,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 58,750 shares of the firm's stock in a transaction on Monday, October 7th. The stock was sold at an average price of $19.57, for a total value of $1,149,737.50. Following the sale, the chief operating officer now directly owns 630,166 shares in the company, valued at $12,332,348.62. This trade represents a 8.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Andrew Dudum sold 78,127 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74. Following the completion of the transaction, the chief executive officer now owns 109,956 shares in the company, valued at approximately $3,256,896.72. The trade was a 41.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,085,157 shares of company stock worth $26,765,193 over the last ninety days. Company insiders own 17.71% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Piper Sandler reaffirmed a "neutral" rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Bank of America downgraded Hims & Hers Health from a "buy" rating to an "underperform" rating and cut their price objective for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. TD Cowen reiterated a "buy" rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a "buy" rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $22.80.

Hims & Hers Health Trading Down 0.6 %

HIMS traded down $0.16 during midday trading on Friday, hitting $26.20. 17,248,361 shares of the company traded hands, compared to its average volume of 10,078,416. The company has a market capitalization of $5.72 billion, a price-to-earnings ratio of 59.55 and a beta of 1.25. The business has a 50 day simple moving average of $25.78 and a two-hundred day simple moving average of $21.27. Hims & Hers Health, Inc. has a 52-week low of $8.09 and a 52-week high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's revenue for the quarter was up 77.1% on a year-over-year basis. During the same period last year, the company earned ($0.04) EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.